Praxis Precision Medicines Inc. Common Stock (PRAX)
Stock · NASDAQ · Health Care
$242.34as of 10/16/2026
Price chart
Active signals
PRAX Signal Track Record
How signals performed across all stocks →What PRAX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | +5.9% | 62% | September 23, 2026 |
| Bollinger Band Breakout | 27 | +0.7% | 56% | August 6, 2026 |
| Bollinger Band Breakdown | 16 | +22.3% | 75% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 6 | +13.5% | 50% | September 15, 2026 |
| Any 20-session window (baseline) | +4.7% | 58% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and d…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 168
- Website
- praxismedicines.com/
Fundamentals
- 1-day range
- $242.61$251.78
- Market cap
- $10.32B
- P/E (trailing)
- —
- P/E (forward)
- -25.79
- EPS (trailing)
- $-13.37
- Dividend yield
- —
- Beta
- 2.88
- Avg. volume
- 430.8K
How Praxis Precision Medicines Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Feb 28, 2025 · via SEC EDGAR / Finnhub
Forecasts
21 analyst ratings
Praxis Precision Medicines Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PRAXPraxis Precision Medicines Inc. Common Stock$241.76▼ 2.61%Market cap $10.32BP/E —$50.56$392.7
- CYTKCytokinetics Incorporated Common Stock$61.95▼ 3.08%Market cap $10.13BP/E —$54.3$88.31
- RDYDr. Reddy's Laboratories Ltd Common Stock$13.07▲ 1.32%Market cap $10.11BP/E 31.61$1,101$1,415
- SMMTSummit Therapeutics Inc. Common Stock$14.63▼ 4.81%Market cap $10.80BP/E —$12.07$29.23
- AXSMAxsome Therapeutics Inc. Common Stock$157.14▼ 2.87%Market cap $10.81BP/E —$120.12$260.19
- ABVXAbivax SA American Depositary Shares$88.13▼ 4.60%Market cap $11.19BP/E —$60.45$139
- PTGXProtagonist Therapeutics Inc. Common Stock$128.75▼ 5.71%Market cap $9.40BP/E 107.21$73.08$160.81
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines Inc. Common Stock | $10.32B | — | $241.76 | ▼ 2.61% | $50.56$392.7 |
| CYTK Cytokinetics Incorporated Common Stock | $10.13B | — | $61.95 | ▼ 3.08% | $54.3$88.31 |
| RDY Dr. Reddy's Laboratories Ltd Common Stock | $10.11B | 31.61 | $13.07 | ▲ 1.32% | $1,101$1,415 |
| SMMT Summit Therapeutics Inc. Common Stock | $10.80B | — | $14.63 | ▼ 4.81% | $12.07$29.23 |
| AXSM Axsome Therapeutics Inc. Common Stock | $10.81B | — | $157.14 | ▼ 2.87% | $120.12$260.19 |
| ABVX Abivax SA American Depositary Shares | $11.19B | — | $88.13 | ▼ 4.60% | $60.45$139 |
| PTGX Protagonist Therapeutics Inc. Common Stock | $9.40B | 107.21 | $128.75 | ▼ 5.71% | $73.08$160.81 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- JP Morgan Initiates Coverage On Praxis Precision Medicine with Overweight Rating, Announces Price Target of $700benzinga · 10/16/2026
- HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price TargetBenzinga · 10/6/2026
- BTIG Maintains Buy on Praxis Precision Medicine, Raises Price Target to $826Benzinga · 10/6/2026
- Praxis Precision Medicine Q2 2026 Earnings Call TranscriptBenzinga · 10/6/2026
- Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/2/2026
- HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price TargetBenzinga · 9/24/2026
- Needham Reiterates Buy on Praxis Precision Medicine, Maintains $582 Price TargetBenzinga · 9/24/2026
- Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)SeekingAlpha · 9/12/2026
Insider Activity
Insider Actions →- Marcio Souza · July 8, 2026 · Gift2.6K
- Marcio Souza · July 8, 2026 · Gift20.5K
- Jill DeSimone · June 24, 2026 · Sale683 @ $306.77
- Jill DeSimone · June 24, 2026 · Sale320 @ $305.31
- Jill DeSimone · June 24, 2026 · Sale120 @ $303.13
- Jill DeSimone · June 24, 2026 · Sale10 @ $301.44
- Jill DeSimone · June 24, 2026 · Option Exercise3.0K @ $147.3
- Jill DeSimone · June 24, 2026 · Option Exercise8.6K @ $44.25
- Jill DeSimone · June 24, 2026 · Sale837 @ $315.71
- Jill DeSimone · June 24, 2026 · Sale1.3K @ $314.9
- Jill DeSimone · June 24, 2026 · Sale504 @ $313.66
- Jill DeSimone · June 24, 2026 · Sale1.0K @ $312.83
- Jill DeSimone · June 24, 2026 · Sale2.9K @ $311.91
- Jill DeSimone · June 24, 2026 · Sale1.8K @ $310.89
- Jill DeSimone · June 24, 2026 · Sale999 @ $309.38
Institutional Ownership
March 31, 2026
- Total shares held
- 31.45M
- Total value held
- $9.86B
- Institutional holders
- 290
- Unknown3.46M
- Unknown2.47M
- Unknown2.32M
- Unknown2.16M
- Unknown2.04M
- Unknown1.75M
- Unknown1.22M
- Unknown963.4K
- Unknown949.2K
- Unknown885.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Praxis Precision Announces Inducement Grants Under Nasdaq Rule
Praxis Precision Medicines disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4). This move is a compliance measure aimed at meeting Nasdaq’s shareholder requirements and may affect the company’s share structure. The announcement is a routine regulatory update rather than a new product or earnings event.
Praxis Precision Announces Inducement Grants Under Nasdaq Rule. Praxis Precision Medicines disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4). This move is a compliance measure aimed at meeting Nasdaq’s shareholder requirements and may affect the company’s share structure. The announcement is a routine regulatory update rather than a new product or earnings event.